Eribulin mesylate
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
266 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 32 | 94 | 39 | 4 | 25 | 176 |
| Male breast neoplasms | D018567 | — | — | — | 1 | — | 1 | — | 2 |
| Drug-related side effects and adverse reactions | D064420 | — | T88.7 | — | — | — | 1 | — | 1 |
| Neurotoxicity syndromes | D020258 | — | G92 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Triple negative breast neoplasms | D064726 | — | — | 12 | 29 | 13 | — | 3 | 53 |
| Neoplasms | D009369 | — | C80 | 30 | 8 | 2 | — | — | 34 |
| Sarcoma | D012509 | — | — | 7 | 9 | 2 | — | 1 | 16 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | 3 | 7 | 7 | — | — | 16 |
| Recurrence | D012008 | — | — | 2 | 4 | 2 | — | 1 | 8 |
| Carcinoma | D002277 | — | C80.0 | 5 | 3 | 1 | — | — | 7 |
| Non-small-cell lung carcinoma | D002289 | — | — | 3 | 4 | 1 | — | — | 7 |
| Brain neoplasms | D001932 | EFO_0003833 | C71 | 2 | 4 | 1 | — | — | 6 |
| Urinary bladder neoplasms | D001749 | — | C67 | 1 | 3 | 1 | — | — | 4 |
| Transitional cell carcinoma | D002295 | — | — | 2 | 2 | 1 | — | — | 4 |
Show 8 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 4 | 1 | — | — | — | 5 |
| Ovarian epithelial carcinoma | D000077216 | — | — | 3 | 1 | — | — | — | 4 |
| Lung neoplasms | D008175 | — | C34.90 | 2 | 3 | — | — | — | 4 |
| Prostatic neoplasms | D011471 | — | C61 | 2 | 2 | — | — | — | 4 |
| Liposarcoma | D008080 | — | — | 3 | 2 | — | — | — | 4 |
| Inflammatory breast neoplasms | D058922 | — | — | 1 | 3 | — | — | — | 3 |
| Melanoma | D008545 | — | — | 2 | 2 | — | — | — | 3 |
| Leiomyosarcoma | D007890 | — | — | 2 | 2 | — | — | — | 3 |
| Colorectal neoplasms | D015179 | — | — | 2 | 2 | — | — | — | 3 |
| Urethral neoplasms | D014523 | EFO_0003846 | — | — | 2 | — | — | — | 2 |
Show 29 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lymphoma | D008223 | — | C85.9 | 2 | — | — | — | — | 2 |
| Skin neoplasms | D012878 | EFO_0004198 | C44 | 1 | — | — | — | — | 1 |
| Cutaneous malignant melanoma | D000096142 | — | — | 1 | — | — | — | — | 1 |
| Abdominal neoplasms | D000008 | — | — | 1 | — | — | — | — | 1 |
| Retroperitoneal neoplasms | D012186 | — | — | 1 | — | — | — | — | 1 |
| Renal insufficiency | D051437 | — | N19 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Peripheral nervous system diseases | D010523 | — | G64 | — | — | — | — | 2 | 2 |
| Alopecia areata | D000506 | EFO_0004192 | L63 | — | — | — | — | 1 | 1 |
| Alopecia | D000505 | — | L64 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
No data
Target
No data
Variants
No data
Financial
No data
Trends
No data
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
475 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use